A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients

被引:207
作者
Dai, HY
van't Veer, L
Lamb, J
He, YD
Mao, M
Fine, BM
Bernards, R
de Vijver, MV
Deutsch, P
Sachs, A
Stoughton, R
Friend, S
机构
[1] Merck & Co Inc, Merck Res Labs, W Point, PA 19486 USA
[2] Rosetta Inpharmat LLC, Seattle, WA USA
[3] Netherlands Canc Inst, Div Diagnost Oncol Radiotherapy & Mol Carcinogene, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Ctr Biomed Genet, Amsterdam, Netherlands
[5] GHC Technol Inc, La Jolla, CA USA
关键词
D O I
10.1158/0008-5472.CAN-04-3953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer comprises a group of distinct subtypes that despite having similar histologic appearances, have very different metastatic potentials. Being able to identify the biological driving force, even for a subset of patients, is crucially important given the large population of women diagnosed with breast cancer. Here, we show that within a subset of patients characterized by relatively high estrogen receptor expression for their age, the occurrence of metastases is strongly predicted by a homogeneous gene expression pattern almost entirely consisting of cell cycle genes (5-year odds ratio of metastasis, 24.0; 95% confidence interval, 6.0-95.5). Overexpression of this set of genes is clearly associated with an extremely poor outcome, with the 10-year metastasis-free probability being only 24% for the poor group, compared with 85% for the good group. In contrast, this gene expression pattern is much less correlated with the outcome in other patient subpopulations. The methods described here also illustrate the value of combining clinical variables, biological insight, and machine-learning to dissect biological complexity. Our work presented here may contribute a crucial step towards rational design of personalized treatment.
引用
收藏
页码:4059 / 4066
页数:8
相关论文
共 36 条
  • [1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [2] Gene-expression profiles predict survival of patients with lung adenocarcinoma
    Beer, DG
    Kardia, SLR
    Huang, CC
    Giordano, TJ
    Levin, AM
    Misek, DE
    Lin, L
    Chen, GA
    Gharib, TG
    Thomas, DG
    Lizyness, ML
    Kuick, R
    Hayasaka, S
    Taylor, JMG
    Iannettoni, MD
    Orringer, MB
    Hanash, S
    [J]. NATURE MEDICINE, 2002, 8 (08) : 816 - 824
  • [3] Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853
    Bijker, N
    Peterse, JL
    Duchateau, L
    Julien, JP
    Fentiman, IS
    Duval, C
    Di Palma, S
    Simony-Lafontaine, J
    de Mascarel, I
    van de Vijver, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2263 - 2271
  • [4] Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: Relation to age and lymph node status
    Collett, K
    Hartveit, F
    Skjaerven, R
    Maehle, BO
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (11) : 920 - 925
  • [5] DeRisi J, 1996, NAT GENET, V14, P457
  • [6] Estrogen receptor status in BRCA1- and BRCA2-related breast cancer:: The influence of age, grade, and histological type
    Foulkes, WD
    Metcalfe, K
    Sun, P
    Hanna, WM
    Lynch, HT
    Ghadirian, P
    Tung, N
    Olopade, OI
    Weber, BL
    McLennan, J
    Olivotto, IA
    Bégin, LR
    Narod, SA
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (06) : 2029 - 2034
  • [7] BOOSTING A WEAK LEARNING ALGORITHM BY MAJORITY
    FREUND, Y
    [J]. INFORMATION AND COMPUTATION, 1995, 121 (02) : 256 - 285
  • [8] Gene expression profiling predicts clinical outcome of prostate cancer
    Glinsky, GV
    Glinskii, AB
    Stephenson, AJ
    Hoffman, RM
    Gerald, WL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (06) : 913 - 923
  • [9] Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
    Golub, TR
    Slonim, DK
    Tamayo, P
    Huard, C
    Gaasenbeek, M
    Mesirov, JP
    Coller, H
    Loh, ML
    Downing, JR
    Caligiuri, MA
    Bloomfield, CD
    Lander, ES
    [J]. SCIENCE, 1999, 286 (5439) : 531 - 537
  • [10] Gruvberger S, 2001, CANCER RES, V61, P5979